We are developing technology to produce chemicals through microbial fermentation using renewable biomass resources as feedstock. Primarily targeting the apparel industry, we manufacture dyes and fiber raw materials via microbial fermentation, thereby contributing to reducing environmental impact. Additionally, we are actively pursuing new technological developments beyond microbial fermentation, aiming to supply environmentally conscious materials to the apparel industry by leveraging various technologies.
A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.
At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
CarbGeM is driving innovation in the life sciences through cutting-edge technologies, including regulatory-approved Software as a Medical Device (SaMD). The company empowers diagnostic support, research efficiency, and the standardization and automation of quality control. While addressing social challenges such as a shortage of skilled professionals and regional healthcare disparities, CarbGeM supports medical and industrial sectors by providing accurate and rapid results. Leveraging AI and digital platforms, the company fosters collaboration among healthcare professionals and researchers worldwide. CarbGeM is actively engaged in co-creating the future of medicine and science through open innovation with leading institutions across industry, academia, and government. The company has received numerous honors, including the Tokyo Social Innovation Tech Award 2024.
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.